Jane Huang
2023 - Prelude Therapeutics
In 2023, Jane Huang earned a total compensation of $1.7M as President and Chief Medical Officer at Prelude Therapeutics, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $316,250 |
|---|---|
| Option Awards | $789,033 |
| Salary | $545,833 |
| Other | $3,546 |
| Total | $1,654,662 |
Huang received $789K in option awards, accounting for 48% of the total pay in 2023.
Huang also received $316.3K in non-equity incentive plan, $545.8K in salary and $3.5K in other compensation.
Rankings
In 2023, Jane Huang's compensation ranked 691st out of 3,006 executives tracked by ExecPay. In other words, Huang earned more than 77.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 691 out of 3,006 | 77th |
Division Manufacturing | 390 out of 1,650 | 76th |
Major group Chemicals And Allied Products | 267 out of 918 | 71st |
Industry group Drugs | 262 out of 881 | 70th |
Industry Pharmaceutical Preparations | 168 out of 637 | 74th |
Source: SEC filing on April 26, 2024.
Huang's colleagues
We found two more compensation records of executives who worked with Jane Huang at Prelude Therapeutics in 2023.
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Prelude Therapeutics CEO Krishna Vaddi's 2022 pay falls 53% to $3.3M
April 28, 2023
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019